CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that a member of its Scientific Advisory Board and two of its scientists will be presenting at the Keystone Symposia’s Diabetes Mellitus, Insulin Action and Resistance Conference in Breckenridge, Colorado January 22-27. The presentations will include data on the impact of a new chemical activator of SIRT1, an enzyme shown to increase insulin sensitivity and improve glucose levels when stimulated in pre-clinical models of Type 2 Diabetes.
